Want to see TSE:IZO full AI Analyst Report?
Top Page
Izotropic
(IZO)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.16
▼(-29.57% Downside)
Action:Reiterated
Date:10/01/26
The score is driven primarily by weak financial performance: a pre-revenue model with ongoing losses, negative free cash flow, and a strained balance sheet marked by persistent negative equity and rising debt. Technicals are also soft with the stock trading below major moving averages, partially offset by near-oversold readings. Valuation is constrained by negative earnings and no dividend yield provided.
Positive Factors
Focused Breast-Imaging Product
A focused product addressing breast-cancer detection and diagnostic evaluation gives Izotropic a clearly defined medical-technology niche. If the system achieves clinical and commercial adoption, specialization could support differentiated positioning rather than competing across a broad range of imaging applications.
Negative Factors
No Commercial Revenue
A continued absence of revenue means Izotropic has not yet demonstrated commercial demand or an operating revenue engine. Progress therefore depends on converting IzoView development into sales or leases, leaving results highly sensitive to commercialization timing and execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Breast-Imaging Product
A focused product addressing breast-cancer detection and diagnostic evaluation gives Izotropic a clearly defined medical-technology niche. If the system achieves clinical and commercial adoption, specialization could support differentiated positioning rather than competing across a broad range of imaging applications.
Read all positive factors
Izotropic (IZO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$11.85M
Dividend YieldN/A
Average Volume (3M)20.39K
Price to Earnings (P/E)―
Beta (1Y)-0.15
Revenue GrowthN/A
EPS Growth10.32%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.03
Shares Outstanding69,724,680
10 Day Avg. Volume32,879
30 Day Avg. Volume20,387
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-3.74
Price to Sales (P/S)0.00
P/FCF Ratio-24.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Izotropic Business Overview & Revenue Model
Company Description
Izotropic Corporation operates as a MedTech enterprise, concentrating on the commercialization of diagnostic solutions for breast cancer. Their primary focus lies in developing and offering a breast CT imaging system alongside a 3D CT breast imagi...
How the Company Makes Money
Izotropic’s intended revenue model is primarily tied to commercializing its IzoView Breast CT system in clinical markets. This would typically include revenue from selling or leasing imaging systems to hospitals and imaging centers and generating ...
Izotropic Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
4
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -33.36K | -48.90K | -59.07K | -30.88K | -6.87K |
| EBITDA | -1.41M | -2.14M | -1.60M | -5.33M | -6.63M |
| Net Income | -2.18M | -3.14M | -1.56M | -5.66M | -6.67M |
Balance Sheet | |||||
| Total Assets | 439.78K | 414.73K | 232.38K | 442.11K | 2.27M |
| Cash, Cash Equivalents and Short-Term Investments | 219.71K | 274.11K | 38.60K | 165.69K | 1.86M |
| Total Debt | 3.11M | 2.76M | 2.06M | 2.14M | 2.03M |
| Total Liabilities | 6.06M | 5.27M | 4.08M | 3.52M | 2.64M |
| Stockholders Equity | -5.63M | -4.86M | -3.85M | -3.07M | -374.59K |
Cash Flow | |||||
| Free Cash Flow | -851.25K | -637.37K | -593.57K | -3.30M | -4.79M |
| Operating Cash Flow | -851.25K | -636.23K | -593.57K | -3.27M | -4.76M |
| Investing Cash Flow | 0.00 | -1.14K | 0.00 | -36.18K | -24.23K |
| Financing Cash Flow | 793.63K | 872.78K | 468.18K | 1.61M | 2.58M |
Izotropic Technical Analysis
Negative
0.23
Price Trends
0.23
Negative
0.24
Negative
0.25
Negative
Market Momentum
-0.01
Positive
35.31
Neutral
12.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:IZO, the sentiment is Negative. The current price of 0.23 is above the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.23, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 35.31 is Neutral, neither overbought nor oversold. The STOCH value of 12.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:IZO.
Izotropic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$37.59M | -1.73 | -303.05% | ― | 35.27% | 58.34% | |
44 Neutral | C$16.39M | -6.87 | 56.40% | ― | 89.06% | 37.62% | |
43 Neutral | C$39.91M | -15.19 | 448.05% | ― | ― | 24.65% | |
42 Neutral | C$58.57M | -40.74 | -250.77% | ― | -82.05% | 23.73% | |
41 Neutral | C$11.85M | -4.87 | 40.45% | ― | ― | 10.32% | |
41 Neutral | C$327.05M | -9.02 | 51.23% | 47.06% | 1.46% | -64.85% |
* Healthcare Sector Average
TSE:IZO
Izotropic
0.17
-0.21
-55.41%
TSE:EDT
Spectral Medical
1.16
-0.28
-19.44%
TSE:BUX
BioMark Diagnostics
0.55
0.19
52.78%
TSE:PINK
Perimeter Medical Imaging AI
0.23
-0.01
-6.25%
TSE:SONA
Sona Nanotech Inc
0.33
-0.30
-47.58%
TSE:VPT
VentriPoint Diagnostics
0.09
-0.02
-18.18%
Izotropic Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Izotropic Launches Strategic Private Placement to Fund Working Capital
Positive
Sep 25, 2026
Izotropic Corporation plans to complete a non-brokered private placement with a strategic investor, issuing 750,000 units at $0.20 per unit for gross proceeds of up to $150,000. Each unit comprises one common share and one transferable warrant, wi...
Business Operations and StrategyProduct-Related Announcements
Izotropic Grants RSUs to Consultants to Drive Global Expansion of Breast CT Platform
Positive
Aug 10, 2026
Izotropic Corporation has granted 750,000 Restricted Share Units to various consultants to support financing and broader business development efforts tied to the commercialization of its IzoView breast CT imaging system. The consultants will assis...
Business Operations and StrategyRegulatory Filings and Compliance
Izotropic Grants RSUs to Consultants, Keeps Dilution in Check
Positive
Aug 10, 2026
Izotropic Corporation has granted 750,000 restricted share units to five non‑insider consulting entities at an exercise price of $0.24 per share, under its previously shareholder‑approved long‑term incentive and stock option plan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.